CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 69 filers reported holding CTI BIOPHARMA CORP in Q1 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $5,553,000 | +88.2% | 2,239,300 | +123.9% | 4.54% | +89.8% |
| Q3 2021 | $2,950,000 | -49.0% | 1,000,000 | -56.8% | 2.39% | -39.7% |
| Q2 2021 | $5,786,000 | -20.9% | 2,314,533 | -8.0% | 3.96% | -16.6% |
| Q1 2021 | $7,318,000 | -39.4% | 2,514,647 | -32.9% | 4.75% | -36.8% |
| Q4 2020 | $12,075,000 | +30.2% | 3,749,890 | -13.1% | 7.53% | -13.9% |
| Q3 2020 | $9,274,000 | +1189.8% | 4,313,617 | +596.4% | 8.74% | +1052.0% |
| Q2 2020 | $719,000 | +26.8% | 619,460 | +0.4% | 0.76% | +22.4% |
| Q1 2020 | $567,000 | +10.3% | 616,695 | +89.4% | 0.62% | +25.0% |
| Q4 2019 | $514,000 | +89.0% | 325,610 | +0.1% | 0.50% | +61.6% |
| Q3 2019 | $272,000 | -2.5% | 325,185 | +0.2% | 0.31% | -3.2% |
| Q2 2019 | $279,000 | -10.9% | 324,452 | +0.4% | 0.32% | +9.3% |
| Q1 2019 | $313,000 | +244.0% | 323,026 | +160.6% | 0.29% | +163.6% |
| Q4 2018 | $91,000 | -78.7% | 123,941 | -37.2% | 0.11% | -72.2% |
| Q3 2018 | $427,000 | – | 197,459 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 5,302,063 | $11,452,000 | 6.70% |
| BVF INC/IL | 6,929,690 | $14,968,000 | 1.32% |
| Opaleye Management Inc. | 1,550,000 | $3,348,000 | 0.85% |
| CAXTON CORP | 197,459 | $427,000 | 0.40% |
| NEA Management Company, LLC | 3,750,000 | $8,100,000 | 0.35% |
| ALGERT GLOBAL LLC | 339,349 | $733,000 | 0.16% |
| Orbimed Advisors | 5,000,000 | $10,800,000 | 0.13% |
| Alambic Investment Management, L.P. | 35,665 | $77,000 | 0.06% |
| OXFORD ASSET MANAGEMENT LLP | 433,002 | $928,000 | 0.02% |
| SECTORAL ASSET MANAGEMENT INC | 32,241 | $70,000 | 0.01% |